Patents by Inventor Kostas Kosmatopoulos

Kostas Kosmatopoulos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220249642
    Abstract: The invention relates to the use of an anti-tumour vaccine composed of two peptides of nine amino acids—native cryptic TERT572 (RLFFYRKSV, SEQ ID No. 1), expressed by tumour cells, and the optimised variant thereof TERT572Y (YLFFYRKSV, SEQ ID No. 2), for the treatment of a tumour expressing telomerase reverse transcriptase (TERT), in an HLA-A*0201 patient with a normal gamma glutamine transferase (gGT) level and/or a normal lactate dehydrogenase (LDH) level.
    Type: Application
    Filed: June 9, 2020
    Publication date: August 11, 2022
    Applicant: Vaxon Biotech
    Inventors: Kostantinos (Kostas) Kosmatopoulos, Jeanne Menez-Jamet
  • Publication number: 20200079819
    Abstract: The invention pertains to the use of a tumor vaccine composed of two peptides of nine amino acids—the WT cryptic TERT572 (RLFFYRKSV, SEQ ID No: 1) expressed by tumor cells and its optimized variant TERT572Y (YLFFYRKSV, SEQ ID No: 2)—for treating cancer in a HLA-A*0201-positive patient having a non small cell lung cancer (NSCLC) expressing TElomerase Reverse Transcriptase (TERT), wherein said patient is a never-smoker or a light-former smoker.
    Type: Application
    Filed: May 4, 2018
    Publication date: March 12, 2020
    Applicant: Vaxon Biotech
    Inventors: Kostantinos (Kostas) Kosmatopoulos, Jeanne Menez-Jamet
  • Publication number: 20200078454
    Abstract: The invention pertains to the use of a tumor vaccine composed of two peptides of nine amino acids—the WT cryptic TERT572 (RLFFYRKSV, SEQ ID No: 1) expressed by tumor cells and its optimized variant TERT572Y (YLFFYRKSV, SEQ ID No: 2)—for treating cancer in a HLA-A*0201-positive patient having a non-immunogenic tumor expressing TERT.
    Type: Application
    Filed: May 4, 2018
    Publication date: March 12, 2020
    Applicant: Vaxon Biotech
    Inventors: Kostantinos (Kostas) Kosmatopoulos, Jeanne Menez-Jamet, Catherine Gallou, Aude Rougeot
  • Patent number: 10024868
    Abstract: The present invention provides novel methods and materials for efficiently treating patients having an HLA-B*0702 phenotype, based on peptides representing shared epitopes of tumor antigens. In particular, the invention relates to a method for identifying a HLA-B*0702-restricted peptide which can trigger a cytotoxic response against several antigens from one single multigenic family, and to several such epitopes.
    Type: Grant
    Filed: June 9, 2009
    Date of Patent: July 17, 2018
    Assignee: Vaxon Biotech
    Inventors: Kostantinos (Kostas) Kosmatopoulos, Jeanne Menez-Jamet
  • Patent number: 8900600
    Abstract: The present invention discloses peptides such as an isolated peptide consisting of an immunogenic HLA-A*2402-restricted epitope. For example, the isolated peptide may be selected from the group consisting of KYGVLLKTL (SEQ ID NO:11); RYMRQFVAL (SEQ ID NO: 12); RYVSRLLGI (SEQ ID NO: 13); RYGKGWDLL (SEQ ID NO: 14); RYLVQVQAL (SEQ ID NO: 15); and RYWELSNHL (SEQ ID NO: 16).
    Type: Grant
    Filed: April 2, 2009
    Date of Patent: December 2, 2014
    Assignee: VAXON Biotech
    Inventors: Kostantinos (Kostas) Kosmatopoulos, Jeanne Menez-Jamet
  • Patent number: 8663645
    Abstract: The present invention pertains to the field of vaccination, and more particularly to the fields of antitumor and antiviral vaccination. The invention relates to the use of a native peptide in a medicinal composition, for selecting and/or boosting part of a CTL immune response which has been initiated by an optimized immunogenic peptide derived from said native peptide. The invention also concerns vaccination kits which comprise several doses of optimized peptides and of their cognate native peptides.
    Type: Grant
    Filed: May 9, 2006
    Date of Patent: March 4, 2014
    Assignee: Vaxon Biotech
    Inventor: Kostantinos (Kostas) Kosmatopoulos
  • Patent number: 8465747
    Abstract: The invention provides methods for identifying a HLA-B*0702-restricted cryptic epitope in an antigen, as well as methods for increasing the immunogenicity of HLA-B*0702-restricted cryptic epitopes. The HLA-B*0702-restricted cryptic epitopes and their cognate immunogenic epitopes are useful for stimulating an immune reaction against the cryptic epitopes in a subject. Accordingly, the invention further provides pharmaceutical compositions comprising a HLA-B*0702-restricted cryptic epitope or a cognate immunogenic epitope thereof, and vaccination kits comprising such epitopes. The novel materials of the invention are particularly useful for efficiently treating patients having an HLA-B*0702 phenotype.
    Type: Grant
    Filed: July 12, 2007
    Date of Patent: June 18, 2013
    Assignee: Vaxon Biotech
    Inventors: Kostantinos (Kostas) Kosmatopoulos, Stéphanie Graff-Dubois, Jeanne Menez-Jamet
  • Publication number: 20120082692
    Abstract: The present invention pertains to methods for identifying a HLA-A*2402-restricted cryptic epitope in an antigen, and for increasing its immunogenicity, in order to obtain HLA-A*2402-restricted epitopes able to trigger an immune response against HLA-A*2402-restricted cryptic epitopes. Isolated peptides consisting of cryptic or optimized HLA-A*2402-restricted epitopes are provided.
    Type: Application
    Filed: April 2, 2009
    Publication date: April 5, 2012
    Applicant: VAXON BIOTECH
    Inventors: Kostantinos(Kostas) Kosmatopoulos, Jeanne Menez-Jamet
  • Publication number: 20110256163
    Abstract: The present invention relates to the field of peptide immunotherapy. In particular, the invention pertains to a method for identifying a HLA-B*0702-restricted cryptic epitope in an antigen, and to a method for increasing its immunogenicity. The invention also provides novel methods and materials for efficiently treating patients having an HLA-B*0702 phenotype.
    Type: Application
    Filed: July 12, 2007
    Publication date: October 20, 2011
    Inventors: Kostantinos (Kostas) Kosmatopoulos, Stéphanie Graff-Dubois, Jeanne Menez-Jamet
  • Patent number: 8003773
    Abstract: This invention relates to the field of anticancer therapy, and to the identification of immunogenic peptides derived from the human telomerase reverse transcriptase (hTERT). The present invention relates to polynucleotides encoding hTERT epitopes restricted to MHC class I molecule, analogues thereof and polyepitopes containing such epitopes and/or analogues. Are also included in the present invention, vector and cell comprising such polynucleotides. The present invention also concerns composition comprising hTERT polypeptides, corresponding polynucleotides, vectors and cells, for use in the treatment and/or prevention of cancer.
    Type: Grant
    Filed: July 12, 2007
    Date of Patent: August 23, 2011
    Assignees: Institut Pasteur, INSERM
    Inventors: Pierre Langlade-Demoyen, Fransisco Garcia Pons, Olivier Adotevi, Sylvain Cardinaud, Christine Neuveut, Kostas Kosmatopoulos, Stéphanie Graff-Dubois, Jeanne Menez-Jamet
  • Patent number: 7976843
    Abstract: Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule, is new. Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule comprising selecting at least one peptide (II) of 8-11 amino acids (aa), potentially representing an epitope for Class I presentation, from a protein against which a cytotoxic T cell (CTL) response is to be raised. (II) corresponds to a non-immunogenic peptide with low affinity for Class I molecules. Variants (IIa) of (II) are prepared in which the N-terminal aa is replaced by Tyr and their immunogenicity detected by identifying those that generate a CTL response against target cells expressing the parent protein. Peptide sequences from which active (IIa) are derived are then identified.
    Type: Grant
    Filed: August 6, 2008
    Date of Patent: July 12, 2011
    Assignees: Institut National de la Santa et de la Recherche Medicale (Inserm), Institut Gustave Roussy (IGR)
    Inventors: Kostas Kosmatopoulos, Sophie Tourdot, Antonio Scardino, David Alexandre Gross
  • Publication number: 20090269363
    Abstract: Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule, is new. Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule comprising selecting at least one peptide (II) of 8-11 amino acids (aa), potentially representing an epitope for Class I presentation, from a protein against which a cytotoxic T cell (CTL) response is to be raised. (II) corresponds to a non-immunogenic peptide with low affinity for Class I molecules. Variants (IIa) of (II) are prepared in which the N-terminal aa is replaced by Tyr and their immunogenicity detected by identifying those that generate a CTL response against target cells expressing the parent protein. Peptide sequences from which active (IIa) are derived are then identified.
    Type: Application
    Filed: August 6, 2008
    Publication date: October 29, 2009
    Inventors: Kostas Kosmatopoulos, Sophie Tourdot, Antonio Scardino, David Alexandre Gross
  • Publication number: 20090175892
    Abstract: This invention relates to the field of anticancer therapy, and to the identification of immunogenic peptides derived from the human telomerase reverse transcriptase (hTERT). The present invention relates to polynucleotides encoding hTERT epitopes restricted to MHC class I molecule, analogues thereof and polyepitopes containing such epitopes and/or analogues. Are also included in the present invention, vector and cell comprising such polynucleotides. The present invention also concerns composition comprising hTERT polypeptides, corresponding polynucleotides, vectors and cells, for use in the treatment and/or prevention of cancer.
    Type: Application
    Filed: July 12, 2007
    Publication date: July 9, 2009
    Applicants: INSTITUT PASTEUR, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Pierre Langlade-Demoyen, Fransisco Garcia Pons, Olivier Adotevi, Syvain Cardinaud, Christine Neuveut, Kostas Kosmatopoulos, Stephanie Graff-Dubois, Jeanne Menez-Jamet
  • Publication number: 20080254051
    Abstract: The present invention pertains to the field of vaccination, and more particularly to the fields of antitumor and antiviral vaccination. The invention relates to the use of a native peptide in a medicinal composition, for selecting and/or boosting part of a CTL immune response which has been initiated by an optimized immunogenic peptide derived from said native peptide. The invention also concerns vaccination kits which comprise several doses of optimized peptides and of their cognate native peptides.
    Type: Application
    Filed: May 9, 2006
    Publication date: October 16, 2008
    Inventor: Kostantinos (Kostas) Kosmatopoulos
  • Patent number: 7425606
    Abstract: Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule, is new. Identifying subdominant/cryptic epitopes (I) that are presented by a HLA (human leukocyte antigen) Class I molecule comprising selecting at least one peptide (II) of 8-11 amino acids (aa), potentially representing an epitope for Class I presentation, from a protein against which a cytotoxic T cell (CTL) response is to be raised. (II) corresponds to a non-immunogenic peptide with low affinity for Class I molecules. Variants (IIa) of (II) are prepared in which the N-terminal aa is replaced by Tyr and their immunogenicity detected by identifying those that generate a CTL response against target cells expressing the parent protein. Peptide sequences from which active (IIa) are derived are then identified.
    Type: Grant
    Filed: July 20, 2001
    Date of Patent: September 16, 2008
    Assignees: Institut National de la Sante et de la Recherche Medicale (Inserm), Institut Gustave Roussy (IGR)
    Inventors: Kostas Kosmatopoulos, Sophie Tourdot, Antonio Scardino, Alexandre David Gross
  • Patent number: 7419669
    Abstract: The invention relates to the production of peptide epitopes common to a plurality of antigens of the same multigene family, said epitopes containing at least one common pentapeptide sequence preceded by three amino acids at the N-terminal end and optionally followed by one or two amino acids at the C-terminal end. The invention also relates to polynucleotides coding for said epitopes. Said peptides and polynucleotides can be especially used in anti-tumour immunotherapy.
    Type: Grant
    Filed: March 27, 2003
    Date of Patent: September 2, 2008
    Assignees: Institut Gustave Roussy, Institut National de la Sante et de la Recherche Medicale
    Inventors: Kostas Kosmatopoulos, Stephanie Graff-Dubois
  • Publication number: 20060263381
    Abstract: The invention relates to the production of peptide epitopes common to a plurality of antigens of the same multigene family, said epitopes containing at least one common pentapeptide sequence preceded by three amino acids at the N-terminal end and optionally followed by one or two amino acids at the C-terminal end. The invention also relates to polynucleotides coding for said epitopes. Said peptides and polynucleotides can be especially used in anti-tumour immunotherapy.
    Type: Application
    Filed: March 27, 2003
    Publication date: November 23, 2006
    Applicants: INSTITUT GUSTAVE ROUSSY, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER. MED
    Inventors: Kostas Kosmatopoulos, Stephanie Graff-Dubois
  • Publication number: 20060034856
    Abstract: The invention concerns peptides constituting T epitopes of EphA antigen, exhibited by MHC I. Said peptides are useful in particular in antitumoral immunotherapy.
    Type: Application
    Filed: April 23, 2003
    Publication date: February 16, 2006
    Inventors: Kostas Kosmatopoulos, Pedro Alves
  • Publication number: 20040072240
    Abstract: The invention concerns a method for identifying sub-dominant/cryptic epitopes exhibited by a class I HLA molecule, said method comprising at least the following steps: a) selecting, from the sequence of a protein with respect to which it is desired to induce a cytotoxic T lymphocyte response, at least a peptide sequence of 8 to 11 amino acids capable of constituting an epitope of said protein exhibited by a class I HLA molecule, and corresponding to a peptide with low affinity for said class I HLA molecule and non-immunogenic; b) preparing, for each selected sequence, a variant peptide derived from said sequence, by substituting the N-terminal amino acid with a tyrosine residue; c) determining the immunogenicity of each variant peptide obtained at step b) by selecting, among the latter, each immunogenic peptide, generating a CTL response specific to the target cells expressing the protein wherefrom it is derived and identifying the peptide sequence wherefrom said immunogenic peptide is derived.
    Type: Application
    Filed: October 2, 2003
    Publication date: April 15, 2004
    Inventors: Kostas Kosmatopoulos, Sophie Tourdot, Antonio Scardino, David Alexander Gross